Tebentafusp ± Durvalumab and/or Tremelimumab in Metastatic Cutaneous Melanoma: Updated OS Analysis From IMCgp100-201 Trial

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In this updated analysis of patients with PD-/PD-L1–treated metastatic cutaneous melanoma, tebentafusp, a bispecific therapy targeting gp100 and CD3, plus anti–PD-L1 was associated with a promising 1-year OS rate of 75%.
Format: Microsoft PowerPoint (.ppt)
File Size: 125 KB
Released: June 13, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings